Stock AnalizNanobiotix S.A. NBTX
Biotechnology: Pharmaceutical Preparations · IPO 2020 · data as of November 13, 2026
Nanobiotix S.A. (NBTX) is a healthcare company listed in the US with a market value of about $1.6B. In fiscal year 2025 it had revenue of $38M and net income of -$28M, a net margin of -73.5%.
Its overall Stock Analiz score is 1.2 out of 5 (weak). The strongest part is future growth (3/5); the weakest is value (0/5).
Key numbers: 5-year revenue growth of 66% a year, a 5-year average ROIC of -155%.
Score: 1.2 / 5
Checks passed
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Strong R&D investment or growth above 20%
- 5-year revenue growth above 8% a year
- ROE above 15%
- More cash than debt, or low debt to equity
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Profit margin improving
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
Valuation
Growth and quality
Financials, last 8 years
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $38M | -$7M | $40M | $5M | $3M | $3M | $3M | $4M |
| Net income | -$28M | -$71M | -$44M | -$61M | -$53M | -$41M | -$57M | -$35M |
| Free cash flow | -$40M | -$21M | -$14M | -$40M | -$34M | -$34M | -$47M | -$30M |
| EPS (diluted) | $-0.55 | $-1.39 | $-0.86 | $-1.20 | $-1.05 | $-0.81 | $-1.13 | $-0.68 |
| Net margin | -73.5% | 947.5% | -109.7% | -1194.3% | -1778.0% | -1337.2% | -2003.7% | -872.2% |
| ROIC | — | — | — | — | -155.1% | -40.8% | — | -211.1% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
Does Nanobiotix pay a dividend?
Not currently.
Is Nanobiotix a good stock to buy?
We do not give buy or sell advice. Nanobiotix scores 1.2 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.